The pre-mRNA splicing landscape changes in SF3B1 mutant MDS cells are not fully characterized due to the low number of reported cases of mutant and wild-type SF3B1 MDS samples and/or the use of a population of cells that do not necessarily represent SF3B1 deficient cells16–18. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.